Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants

NCT06524414 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06524414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06524414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 25, 2024
Completion date
May 1, 2027
Enrollment
605 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal disease